We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.
- Authors
Kanda, Tatsuo; Imazeki, Fumio; Azemoto, Ryosaku; Yonemitsu, Yutaka; Mikami, Shigeru; Kita, Kazuhiko; Takashi, Motohide; Sunaga, Masahiko; Wu, Shuang; Nakamoto, Shingo; Tawada, Akinobu; Arai, Makoto; Kato, Keizo; Yoshida, Yu; Koma, Yoshihiro; Fujiwara, Keiichi; Fukai, Kenichi; Suzuki, Noriaki; Yokosuka, Osamu
- Abstract
<bold>Background: </bold>The current standard treatment for patients infected with hepatitis C virus (HCV) of genotype 2 is the combination of peginterferon (PEG-IFN) plus ribavirin (RBV) for 24 weeks.<bold>Aims: </bold>We assessed the sustained virological response (SVR) rates in HCV genotype 2-infected Japanese patients in relation to the duration of treatment.<bold>Methods: </bold>Between 2006 and 2009, among 147 patients with HCV genotype 2-infection in Chiba Prefecture, 138 consecutive patients were finally enrolled. Twenty-one, 97 and 20 patients were treated with PEG-IFN-alfa 2b plus RBV for 16, 24 and 48 weeks, respectively. Epidemiological data and treatment outcomes were retrospectively evaluated. HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v. 2.0.<bold>Results: </bold>The overall SVR rate was 82.6% (114 of 138): treatment-naïve patients, 86.4% (89 of 103); patients with history of previous treatment, 71.4% (25 of 35). Patients treated for 16, 24 and 48 weeks obtained SVR rates of 66.6% (14 of 21), 86.5% (84 of 97) and 80.0 (16 of 20), respectively.<bold>Conclusions: </bold>The SVR rates of PEG-IFN-alfa 2b plus RBV in Japanese patients were similar to those in previous studies. Combination treatment for 24 weeks for some patients infected with HCV genotype 2 may be superior to that for 16 weeks. More precise patient selection will be needed to shorten the combination treatment.
- Subjects
JAPAN; HEPATITIS C treatment; POLYETHYLENE glycol; RIBAVIRIN; EPIDEMIOLOGY; TREATMENT effectiveness; ANTIVIRAL agents; JAPANESE people; DISEASES; ASIANS; COMBINATION drug therapy; COMPARATIVE studies; HEPATITIS viruses; RESEARCH methodology; MEDICAL cooperation; PATIENT compliance; PROTEINS; RECOMBINANT proteins; RESEARCH; EVALUATION research; RETROSPECTIVE studies; CHRONIC hepatitis C; GENOTYPES
- Publication
Digestive Diseases & Sciences, 2011, Vol 56, Issue 11, p3335
- ISSN
0163-2116
- Publication type
journal article
- DOI
10.1007/s10620-011-1750-7